scholarly journals Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema

2019 ◽  
Vol Volume 13 ◽  
pp. 2583-2590
Author(s):  
Tommi Karttunen ◽  
Lasse Nummelin ◽  
Kai Kaarniranta ◽  
Kati Kinnunen
Keyword(s):  
Macular Oedema ◽  
Life Experience ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Dexamethasone Implant

One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab

2020 ◽  
pp. 112067212092727
Author(s):  
Marko Lukic ◽  
Gwyn Williams ◽  
Zaid Shalchi ◽  
Praveen J Patel ◽  
Philip G Hykin ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Diabetic Retinopathy ◽  
Early Treatment ◽  
Macular Oedema ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Foveal Thickness ◽  
Macular Volume ◽  
Central Foveal Thickness ◽  
The Mean

Purpose To assess visual and optical coherence tomography–derived anatomical outcomes of treatment with intravitreal aflibercept (Eylea®) for diabetic macular oedema in patients switched from intravitreal ranibizumab (Lucentis®). Design Retrospective, cohort study. Participants Ninety eyes (of 67 patients) receiving intravitreal anti–vascular endothelial growth factor therapy were included. Methods This is a retrospective, real-life, cohort study. Each patient had visual acuity measurements and optical coherence tomography scans performed at baseline and 12 months after the first injection of aflibercept was given. Main Outcome Measures We measured visual acuities in Early Treatment Diabetic Retinopathy Study letters, central foveal thickness and macular volume at baseline and at 12 months after the first aflibercept injection was given. Results Ninety switched eyes were included in this study. The mean (standard deviation) visual acuity was 63 (15.78) Early Treatment Diabetic Retinopathy Study letters. At baseline, the mean (standard deviation) central foveal thickness was 417.7 (158.4) μm and the mean macular volume was 9.96 (2.44) mm3. Mean change in visual acuity was +4 Early Treatment Diabetic Retinopathy Study letters (p = 0.0053). The mean change in macular volume was −1.53 mm 3 in SW group (p = 0.21), while the change in central foveal thickness was −136.8 μm (p = 0.69). Conclusion There was a significant improvement in visual acuity and in anatomical outcomes in the switched group at 12 months after commencing treatment with aflibercept for diabetic macular oedema.

Are the real‐life outcomes of using aflibercept in diabetic macular oedema comparable to the landmark studies?

2018 ◽  
Vol 97 (2) ◽  
Author(s):  
Aisling K. Higham ◽  
Muhammad I. Tahir ◽  
Kavita Gala ◽  
Georgios Verroiopoulos
Keyword(s):  
Macular Oedema ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Life Outcomes ◽  
The Real

Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: A national Delphi consensus study

2021 ◽  
pp. 112067212110528
Author(s):  
Laurent Kodjikian ◽  
Stephanie Baillif ◽  
Aude Couturier ◽  
Catherine Creuzot-Garcher ◽  
Marie-Noelle Delyfer ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Daily Practice ◽  
Dexamethasone Implant ◽  
Consensus Approach ◽  
Delphi Consensus ◽  
First Line ◽  
Anti Vegf ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone

Purpose The intravitreal dexamethasone implant (DEX-I) is an alternative to anti-VEGF for the first-line treatment of diabetic macular oedema (DME). However, several questions remain regarding its routine use and its place in certain situations not always specified in current recommendations. A national consensus approach was, therefore, initiated by French retinal experts. Methods An iterative Delphi consensus approach was used. A steering committee (SC) of seven experts analysed data from the literature to formulate statements divided into five key areas of treatment. These statements were submitted to the independent and anonymous electronic vote of 87 French retina experts among whom 39 expressed their opinion and therefore constituted the voting panel. Results After two rounds of voting, 22 and 7 of 38 statements received a strong consensus and a good consensus, respectively. The consensus level was higher for statements regarding first-line indications and safety of DEX-I compared to those regarding efficacy assessment, reprocessing time or pathophysiological biomarkers. The panellists recommended the preferential use of DEX-I for patients with limited availability for multiple injections, those who needed to undergo cataract surgery or who had a recent cardiovascular history, and as a therapeutic alternative to anti-VEGF in patients with a history of vitrectomy, retinal serous detachment, hyper-reflective points or dry exudates in optical coherence tomography (OCT). However, some statements proposed by SC experts were not validated. Conclusion This study provides some key recommendations to clinicians treating diabetic macular oedema, which may be useful when using intravitreal dexamethasone implants in daily practice.

Safety of 6000 intravitreal dexamethasone implants

2019 ◽  
Vol 104 (1) ◽  
pp. 39-46 ◽  
Author(s):  
Bindu Rajesh ◽  
Javier Zarranz-Ventura ◽  
Adrian T Fung ◽  
Catharina Busch ◽  
Niroj Kumar Sahoo ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Retinal Detachment ◽  
Macular Oedema ◽  
Real Life ◽  
Cystoid Macular Oedema ◽  
Dexamethasone Implant ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone ◽  
Phakic Eyes

PurposeTo evaluate the real-life safety profile of intravitreal dexamethasone implant injection for various retinal conditions.MethodsRetrospective multicenter analysis of intravitreal dexamethasone implant injections (700 µg) due to various retinal conditions including central retinal venous occlusion (1861 injections), diabetic macular oedema (3104 injections), post-surgical cystoid macular oedema (305 injections) and uveitis (381 injections). The eyes were evaluated mainly for the occurrence of adverse events such as glaucoma, cataract, retinal detachment and endophthalmitis along during the follow-up period.ResultsA total of 6015 injections in 2736 eyes of 1441 patients (mean age of 65.7±12.9 years) were in total analysed over an average period of 18 months (range 6 months to 102 months). A total of 576 eyes (32.5% of the phakic eyes) developed cataract requiring surgical intervention. However, visually insignificant cataract progression was observed in another 259 phakic eyes (14.6%) which did not require surgical removal. A total of 727 eyes (26.5%) experienced an intraocular pressure (IOP) rise of >25 mm Hg, with 155 eyes (5.67%) having a prior history of glaucoma and 572 eyes (20.9%) having new onset IOP rise. Overall, more than 90% of eyes with IOP rise were managed medically, and 0.5% eyes required filtering surgery. Endophthalmitis (0.07%), retinal detachment (0.03%) and vitreous haemorrhage (0.03%) were rare. There was no significant change in visual acuity (p=0.87) and central macular thickness (p=0.12) at the last follow-up.ConclusionThis is the largest real-life study assessing the safety of intravitreal dexamethasone implant injections in various retinal conditions. Cataract progression and intraocular pressure rise are the most common side effects, but are often rather easily manageable.

scholarly journals Long-term efficacy and duration of action of dexamethasone implant, in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema

Eye ◽  
2018 ◽  
Vol 33 (3) ◽  
pp. 411-418 ◽  
Author(s):  
George G. Bastakis ◽  
Dimitris Dimopoulos ◽  
Anastasios Stavrakakis ◽  
George Pappas
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Dexamethasone Implant ◽  
Duration Of Action ◽  
Term Efficacy

Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant

2019 ◽  
Vol 98 (2) ◽  
Author(s):  
Dinah Zur ◽  
Matias Iglicki ◽  
Anna Sala‐Puigdollers ◽  
Jay Chhablani ◽  
Marco Lupidi ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Dexamethasone Implant
Sign in / Sign up

Export Citation Format

Share Document